Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board

13 Aug 2018

Commences study to assess novel RORγt inhibitor for the treatment of psoriasis Recruits key opinion leaders to guide clinical development of its RORγt programs. NIJMEGEN, The Netherlands and Encinitas, California, August 13, 2018 – Escalier Biosciences, BV, a...

Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders

23 Jul 2018

Company to address unmet medical needs in the field of rare metabolic disorders Exclusive IP licensed from Leiden University and Amsterdam UMC Senior industry R&D leader Olivier Morand appointed as Chief Executive Officer and member of the Board of Directors...

VarmX raises €12.5 million to develop modified blood coagulation factor X for treating severe bleeding in patients using anticoagulants

2 Jul 2018

Funding enables clinical stage trials of lead compound PseudoXa € 7.5 million Series A financing from lead investor BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter Financing supplemented by € 5.0 million innovation credit from the...

Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen

14 May 2018

AMSTERDAM, NETHERLANDS – May 14, 2018 – Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of  ImmunoGen, Inc. Dr. Lambert joined ImmunoGen Inc. in 1987 and...

Scenic Biotech: one of Nature Biotechnology Academic Spinouts of 2017

19 Apr 2018

We congratulate Scenic Biotech on being one of Nature Biotechnology Academic Spinouts of 2017. Nature Biotechnology: “… we believe these companies represent some of the best (and most richly financed) science that was commercialized from academia in...

Escalier Biosciences Raises $19 Million to Develop its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases

13 Mar 2018

Advancing Escalier’s drug candidates through human proof-of-concept studies NIJMEGEN, The Netherlands and ENCINITAS, California, – Escalier Biosciences BV, a privately held biopharmaceutical company, today announced the closing of a $19 million Series B financing. The...